4.3 Article

FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells

Journal

ONCOTARGET
Volume 6, Issue 7, Pages 4757-4772

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.3023

Keywords

Triple-negative breast cancers (TNBC); insulin-like growth factor 1 receptor (IGF1R); focal adhesion kinase (FAK); epithelial-mesenchymal transition (EMT); invasion

Funding

  1. Integrated Cell Imaging (ICI) core of Winship Cancer Institute of Emory University
  2. NIH/NCI [P30CA138292]
  3. Glenn Family Foundation
  4. Emory University FIRST Postdoctoral Fellowship (NIH) [K12 GM000680]
  5. [R01CA157754]

Ask authors/readers for more resources

Triple negative breast cancer (TNBC) is a highly metastatic disease that currently lacks effective prevention and treatment strategies. The insulin-like growth factor 1 receptor (IGF1R) and focal adhesion kinase (FAK) signaling pathways function in numerous developmental processes, and alterations in both are linked with a number of common pathological diseases. Overexpression of IGF1R and FAK are closely associated with metastatic breast tumors. The present study investigated the interrelationship between IGF1R and FAK signaling in regulating the malignant properties of TNBC cells. Using small hairpin RNA (shRNA)-mediated IGF1R silencing methods, we showed that IGF1R is essential for sustaining mesenchymal morphologies of TNBC cells and modulates the expression of EMT-related markers. We further showed that IGF1R overexpression promotes migratory and invasive behaviors of TNBC cell lines. Most importantly, IGF1R-driven migration and invasion is predominantly mediated by FAK activation and can be suppressed using pharmacological inhibitors of FAK. Our findings in TNBC cells demonstrate a novel role of the IGF1R/FAK signaling pathway in regulating critical processes involved in the metastatic cascade. These results may improve the current understanding of the basic molecular mechanisms of TNBC metastasis and provide a strong rationale for co-targeting of IGF1R and FAK as therapy for mesenchymal TNBCs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available